SEC Form 4 · accession 0001104659-17-032409
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Paul Harris
Director
Period of report
May 11, 2017
Accepted (ET)
May 12, 2017 · 9:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par valueF2 | May 11, 2017 | A | 7,500 | $0.00 | A | 601,594 | D | |
| Common Shares, without par value | holding | — | — | — | 600,188 | I | By spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F3 | $1.56 | May 11, 2017 | A | 15,000 | A | — | May 11, 2017 | Common Shares, without par value | 15,000 | 15,000 | D |
Explanation of responses
- F1Restricted Stock Units, all of which vest on May 11, 2018, subject to the director's continued service on the Board as of such date.
- F2Includes 594,094 shares of Common Stock and 7,500 Restricted Stock Units.
- F3The option vests in one installment on May 11, 2018, subject to the director's continued service on the Board as of such date.